<DOC>
	<DOC>NCT00835068</DOC>
	<brief_summary>The primary objective of this observational study is to collect safety data on reformulated BeneFIX as prescribed in routine clinical practice conditions in France. The secondary objectives are to collect data on the clinical course of individuals treated with reformulated BeneFIX and on the ease of reformulated BeneFIX.</brief_summary>
	<brief_title>Post Marketing Observational Study of Reformulated BeneFIX</brief_title>
	<detailed_description>No sampling</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Subjects with Hemophilia B already receiving or starting treatment with reformulated BeneFIX. Subjects who have dated and signed the informed consent form. Ongoing treatment of Hemophilia B by a product other than reformulated BeneFIX. Participation in the European prospective registry of patients with Hemophilia B treated with BeneFIX (Wyeth protocol 3090A101039).</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Hemophilia B</keyword>
	<keyword>observational</keyword>
	<keyword>post marketing study</keyword>
</DOC>